Indications and uses
Helps prevent sunburn. If used as directed with other sun protection measures (see Directions ), helps decrease the risk of skin cancer and early skin aging caused by the sun.
Helps prevent sunburn. If used as directed with other sun protection measures (see Directions ), helps decrease the risk of skin cancer and early skin aging caused by the sun.
Apply liberally 30 minutes before sun exposure Reapply at least every two hours Use a water-resistant sunscreen if swimming or sweating Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To help decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF of 15 or higher and other sun protection measures including: - limit time in the sun, especial...
Protect this product from excessive heat and direct sun.
Drug Facts
Avobenzone (3.0%)
Octinoxate (7.5%)
Sunscreen
For external use only
Keep out of reach of children.
Water/Aqua/Eau, Carthamus Tinctorius (Safflower) Oleosomes, Butylene Glycol, Glycerin, C12-15 Alkyl Benzoate, Polysorbate 80, Dimethyl Capramide, Sodium Hyaluronate Crosspolymer, Cananga Odorata Flower Oil, Eucalyptus Globulus Leaf Oil, Lavandula Hybrida Oil, Lavendula Spica (Lavender) Flower Oil, Laminaria Ochroleuca Extract, Palmaria Palmata Extract, Oligopeptide-34, Dipotassium Glycyrrhizate, Lactobacillus/Pumpkin Fruit Ferment Filtrate, Niacinamide, Zinc Glycinate, Polysorbate 60, Ammonium Acryloyldimethyltaurate/VP Copolymer, Vinyl Dimethicone/Methicone Silsesquioxane Crosspolymer, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Isohexadecane, Butylene Glycol Behenate, Glyceryl Polyacrylate, Disodium EDTA, Sodium Hydroxide, Ethylhexylglycerin, Phenoxyethanol.
Call toll free 1-800-831-5150 in the US.
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68479-213-00 | 2022-07-29 | C162847 | 48780-1 | e4f33bdf-9d71-d8a0-e053-dadaa90a6e4e | PureLight SPF50 |
| 68479-213-01 | 2022-07-29 | C162847 | 48780-1 | e4f33bdf-9d71-d8a0-e053-dadaa90a6e4e | PureLight SPF50 |
| 68479-213-02 | 2022-07-29 | C162847 | 48780-1 | e4f33bdf-9d71-d8a0-e053-dadaa90a6e4e | PureLight SPF50 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68479-213-00 | PureLight SPF50 | 2 mL in 1 POUCH | LOTION | 2 | 3 | |
| 68479-213-01 | PureLight SPF50 | 10 mL in 1 TUBE | LOTION | 10 | 3 | |
| 68479-213-02 | PureLight SPF50 | 50 mL in 1 TUBE | LOTION | 50 | 3 | |
| 68479-213-02 | PureLight SPF50 | 1 in 1 CARTON | LOTION | 1 | 3 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Avobenzone | ACTIVE INGREDIENT | G63QQF2NOX | 2 | |
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 2 | |
| Avobenzone | ACTIVE MOIETY | G63QQF2NOX | 2 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 2 | |
| Alkyl (C12-15) Benzoate | INACTIVE INGREDIENT | A9EJ3J61HQ | 2 | |
| Ammonium Acryloyldimethyltaurate/VP Copolymer | INACTIVE INGREDIENT | W59H9296ZG | 2 | |
| Butylene Glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 2 | |
| Butylene Glycol Behenate | INACTIVE INGREDIENT | X0IW5BP6ZL | 2 | |
| Cananga Oil | INACTIVE INGREDIENT | 8YOY78GNNX | 2 | |
| Carthamus Tinctorius Seed Oleosomes | INACTIVE INGREDIENT | 9S60Q72309 | 2 | |
| Dimethyl Capramide | INACTIVE INGREDIENT | O29Y6X2JEZ | 2 | |
| Dulse | INACTIVE INGREDIENT | 7832HOY4ZQ | 2 | |
| Edetate Disodium | INACTIVE INGREDIENT | 7FLD91C86K | 2 | |
| Ethylhexylglycerin | INACTIVE INGREDIENT | 147D247K3P | 2 | |
| Eucalyptus Oil | INACTIVE INGREDIENT | 2R04ONI662 | 2 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| Glycyrrhizinate Dipotassium | INACTIVE INGREDIENT | CA2Y0FE3FX | 2 | |
| Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer (45000 MPA.S at 1%) | INACTIVE INGREDIENT | 86FQE96TZ4 | 2 | |
| Isohexadecane | INACTIVE INGREDIENT | 918X1OUF1E | 2 | |
| Laminaria Ochroleuca | INACTIVE INGREDIENT | 4R2124HE76 | 2 | |
| Lavandin Oil | INACTIVE INGREDIENT | 9RES347CKG | 2 | |
| Lavender Oil | INACTIVE INGREDIENT | ZBP1YXW0H8 | 2 | |
| Niacinamide | INACTIVE INGREDIENT | 25X51I8RD4 | 2 | |
| Phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 2 | |
| Polysorbate 60 | INACTIVE INGREDIENT | CAL22UVI4M | 2 | |
| Polysorbate 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 2 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 2 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 2 | |
| Zinc Glycinate | INACTIVE INGREDIENT | 681VJX72FE | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68479-213 | 68479-213-02, 68479-213-00, 68479-213-01 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / INTRADERMAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPRAY / NASAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBCUTANEOUS | 1 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRATUMOR | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAVENOUS | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, COATED / ORAL | 0.08 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / TOPICAL | ADJ PH | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 0.05 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRABURSAL | 0.01 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / OPHTHALMIC | 0.05 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| Niacinamide | NIACINAMIDE | 25X51I8RD4 | INJECTION / INTRAMUSCULAR | 2.5 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SUBCUTANEOUS | 31.45 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / RESPIRATORY (INHALATION) | 43 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRADERMAL | ADJ PH | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | AEROSOL, FOAM / TOPICAL | 0.98 %w/w | ||
| Niacinamide | NIACINAMIDE | 25X51I8RD4 | INJECTION / INTRAVENOUS | 2.5 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| Polysorbate 60 | POLYSORBATE 60 | CAL22UVI4M | EMULSION / ORAL | 20 mg/1ml | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / ORAL | 9120 mg | ||
| Niacinamide | NIACINAMIDE | 25X51I8RD4 | GEL / TOPICAL | 25 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / RECTAL | NA | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVESICAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRATHECAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | PASTE / DENTAL | 0.6 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, COATED / ORAL | 0.21 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, CHEWABLE / ORAL | 84 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 900 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / IONTOPHORESIS | 0.1 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY, METERED / NASAL | 4 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, COATED / ORAL | 0.04 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAOCULAR | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / PARENTERAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / AURICULAR (OTIC) | ADJ PH | ||
| Polysorbate 60 | POLYSORBATE 60 | CAL22UVI4M | CREAM / VAGINAL | 200 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, COATED PELLETS / ORAL | 2 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / EPIDURAL | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 0.4 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | EMULSION / OPHTHALMIC | 26 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | ENEMA / RECTAL | 0.44 %v/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | LIQUID / NASAL | 2 mg/1ml | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRACAUDAL | ADJ PH | ||
| Phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | CREAM, AUGMENTED / TOPICAL | 10 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | NA | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | POWDER / RESPIRATORY (INHALATION) | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAMUSCULAR | ADJ PH |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 78139a5a-f5bf-4a31-9e16-e95371b0e9d9 | 880d83ff-3e25-4409-b8bb-7e8d1db2ee6d | 2017-12-11 | Warnings | 78139a5a-f5bf-4a31-9e16-e95371b0e9d9 880d83ff-3e25-4409-b8bb-7e8d1db2ee6d |
Adverse event summaries are temporarily unavailable. Other product information remains available.